CAR-T Meeting 2022 | Managing patients with hematological malignancies treated with CAR-Ts during the COVID-19 pandemic
Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, talks on managing patients with hematological malignancies treated with chimeric antigen receptor T-cell (CAR-T) therapy during the COVID-19 pandemic. The pandemic has had a significant impact on the delivery of CAR-T therapy and other cellular therapies. Dr Greco explains that during this challenging time, CAR-T centers received guidelines on how to manage patients with hematological malignancies treated with CAR-T therapy who got infected with COVID-19. In addition, she explains that at the peak of the pandemic, the most urgent cases were prioritized for treatment with CAR-T and other cellular therapies. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
